{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Oka S"],"funding":["Japan Research Foundation for Clinical Pharmacology","Astellas Pharma Inc.","the Japan Society for the Promotion of Science","National Hospital Organization","The Nakatomi Foundation","Abbott Japan Co., Ltd.","the Ministry of Health, Labour, and Welfare of Japan","Merck Sharp and Dohme Inc.","Chugai Pharmaceutical Co., Ltd.","Takeda Science Foundation","Mitsubishi Tanabe Pharma Corporation","Bristol-Myers Squibb Co.","Eisai Co., Ltd.","Japan Agency for Medical Research and Development","Mitsui Sumitomo Insurance Welfare Foundation","Daiwa Securities Health Foundation","Teijin Pharma Limited","Pfizer Japan Inc.","Takeda Pharmaceutical Company Limited"],"pagination":["363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9962840"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["59(2)"],"pubmed_abstract":["Chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway diseases (ADs), are common complications of rheumatoid arthritis (RA). Rheumatoid factor (RF) and anti-citrullinated peptide antibodies are reported to be associated with CLD in RA patients. The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (Abs) is associated with clinically amyopathic dermatomyositis developing into rapidly progressive ILD. However, few studies on anti-MDA5 Abs in RA have been published. Here, we analyzed the association of anti-MDA5 Abs with CLD complications in RA. Anti-MDA5 Abs were quantified in sera from RA patients with or without CLD. Anti-MDA5 Ab levels were higher in RA patients with ADs than without (mean ± SDM, 4.4 ± 2.4 vs. 4.0 ± 4.2, <i>p =</i> 0"],"journal":["Medicina (Kaunas, Lithuania)"],"pubmed_title":["Antibodies against Serum Anti-Melanoma Differentiation-Associated Gene 5 in Rheumatoid Arthritis Patients with Chronic Lung Diseases."],"pmcid":["PMC9962840"],"funding_grant_id":["22591090, 26293123, 15K09543, 18K08402"],"pubmed_authors":["Furukawa H","Komiya A","Hashimoto A","Okamoto A","Yoshikawa N","Fukui N","Higuchi T","Shimada K","Matsui T","Oka S","Tohma S","Katayama M","Saisho K","Migita K"],"additional_accession":[]},"is_claimable":false,"name":"Antibodies against Serum Anti-Melanoma Differentiation-Associated Gene 5 in Rheumatoid Arthritis Patients with Chronic Lung Diseases.","description":"Chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway diseases (ADs), are common complications of rheumatoid arthritis (RA). Rheumatoid factor (RF) and anti-citrullinated peptide antibodies are reported to be associated with CLD in RA patients. The presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies (Abs) is associated with clinically amyopathic dermatomyositis developing into rapidly progressive ILD. However, few studies on anti-MDA5 Abs in RA have been published. Here, we analyzed the association of anti-MDA5 Abs with CLD complications in RA. Anti-MDA5 Abs were quantified in sera from RA patients with or without CLD. Anti-MDA5 Ab levels were higher in RA patients with ADs than without (mean ± SDM, 4.4 ± 2.4 vs. 4.0 ± 4.2, <i>p =</i> 0","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-04T21:43:15.555Z","creation":"2025-04-04T21:43:15.555Z"},"accession":"S-EPMC9962840","cross_references":{"pubmed":["36837566"],"doi":["10.3390/medicina59020363"]}}